Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines.
Age Factors
Child, Preschool
Female
Hospitalization
Humans
Incidence
Infant
Lung
/ virology
Male
Nasopharynx
/ virology
Philippines
/ epidemiology
Prospective Studies
Respiratory Syncytial Virus Infections
/ epidemiology
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
Respiratory Tract Infections
/ epidemiology
Risk Factors
cohort study
lower respiratory tract illness
pulse oximetry
respiratory syncytial virus
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
18
09
2018
revised:
09
02
2019
accepted:
14
02
2019
pubmed:
21
3
2019
medline:
28
1
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) is one of the main viral causes of lower respiratory tract illness (LRTI), especially in young children. RSV vaccines, including maternal and infant vaccines, are under development; however, more epidemiological studies are needed to develop effective vaccination strategies. To estimate detailed age-specific incidence rates and severity of RSV-associated LRTI (RSV-LRTI) using data from a community-based prospective cohort study in the Philippines. Cohort children who visited health facilities due to acute respiratory symptoms were identified, and nasopharyngeal swabs were collected to detect RSV. The severity of RSV-LRTI was assessed using the severity definition proposed by the World Health Organization. Risk factors for developing RSV-LRTI and contribution of SpO A total of 395 RSV episodes which occurred in children aged 2-59 months were categorised as 183 RSV-LRTI, 72 as severe RSV-LRTI and 29 as very severe RSV-LRTI. Children aged 3-5 months had the highest incidence rate of RSV-LRTI, at 207.4 per 1000 child-years (95% CI: 149.0-279.5). Younger age group, place of living and low educational level of caregivers were associated with developing RSV-LRTI. Clinical manifestations had low levels of agreement with hypoxaemia as measured by pulse oximeter. The highest burden of RSV was observed in young infants aged 3-5 months, whereas the burden was also high in those aged 12-20 months. Future vaccination strategies should consider the protection of older children, especially those aged one year, as well as young infants.
Sections du résumé
BACKGROUND
Respiratory syncytial virus (RSV) is one of the main viral causes of lower respiratory tract illness (LRTI), especially in young children. RSV vaccines, including maternal and infant vaccines, are under development; however, more epidemiological studies are needed to develop effective vaccination strategies.
OBJECTIVES
To estimate detailed age-specific incidence rates and severity of RSV-associated LRTI (RSV-LRTI) using data from a community-based prospective cohort study in the Philippines.
PATIENTS/METHODS
Cohort children who visited health facilities due to acute respiratory symptoms were identified, and nasopharyngeal swabs were collected to detect RSV. The severity of RSV-LRTI was assessed using the severity definition proposed by the World Health Organization. Risk factors for developing RSV-LRTI and contribution of SpO
RESULTS
A total of 395 RSV episodes which occurred in children aged 2-59 months were categorised as 183 RSV-LRTI, 72 as severe RSV-LRTI and 29 as very severe RSV-LRTI. Children aged 3-5 months had the highest incidence rate of RSV-LRTI, at 207.4 per 1000 child-years (95% CI: 149.0-279.5). Younger age group, place of living and low educational level of caregivers were associated with developing RSV-LRTI. Clinical manifestations had low levels of agreement with hypoxaemia as measured by pulse oximeter.
CONCLUSION
The highest burden of RSV was observed in young infants aged 3-5 months, whereas the burden was also high in those aged 12-20 months. Future vaccination strategies should consider the protection of older children, especially those aged one year, as well as young infants.
Identifiants
pubmed: 30891896
doi: 10.1111/irv.12639
pmc: PMC6586181
doi:
Substances chimiques
Respiratory Syncytial Virus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-353Investigateurs
Jhoys M Landicho
(JM)
Mark Donald C Reñosa
(MDC)
Marianette T Inobaya
(MT)
Portia P Alday
(PP)
Amado O Tandoc
(AO)
Informations de copyright
© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Scand J Infect Dis. 2006;38(8):690-5
pubmed: 16857616
J Clin Microbiol. 2005 Jan;43(1):36-40
pubmed: 15634948
Trop Med Int Health. 2008 Jul;13(7):914-26
pubmed: 18482199
J Glob Health. 2015 Dec;5(2):020416
pubmed: 26682048
Clin Infect Dis. 2008 Jan 1;46(1):50-7
pubmed: 18171213
Bull World Health Organ. 2016 Dec 1;94(12):893-902
pubmed: 27994282
J Gen Virol. 2017 Dec;98(12):2912-2913
pubmed: 29087278
Am J Trop Med Hyg. 2017 Jul;97(1):68-76
pubmed: 28719310
Vaccine. 2018 Jul 25;36(31):4693-4700
pubmed: 29941327
Braz J Infect Dis. 2006 Oct;10(5):357-61
pubmed: 17293926
Lancet Infect Dis. 2018 Oct;18(10):e295-e311
pubmed: 29914800
J Infect Dis. 2018 Aug 24;218(7):1045-1053
pubmed: 29722817
Br Med J. 1976 Jul 31;2(6030):274-6
pubmed: 953560
Pediatr Infect Dis J. 2011 Sep;30(9):778-84
pubmed: 21487330
Trop Med Int Health. 2005 Mar;10(3):240-5
pubmed: 15730508
J Infect Dis. 2016 Dec 1;214(11):1712-1716
pubmed: 27655869
J Infect. 2014 Mar;68(3):281-9
pubmed: 24269675
J Pediatr. 2003 Nov;143(5 Suppl):S118-26
pubmed: 14615710
Virus Res. 2011 Dec;162(1-2):80-99
pubmed: 21963675
Lancet Public Health. 2017 Jul 31;2(8):e367-e374
pubmed: 28804787
Pediatr Rev. 2014 Dec;35(12):519-30
pubmed: 25452661
Vaccine. 2016 Jan 4;34(2):190-197
pubmed: 26100926
Influenza Other Respir Viruses. 2019 Jul;13(4):339-353
pubmed: 30891896
J Gen Virol. 1998 Sep;79 ( Pt 9):2221-9
pubmed: 9747732
Bull World Health Organ. 2004 Dec;82(12):914-22
pubmed: 15654405
Pediatr Infect Dis J. 2014 Mar;33(3):267-71
pubmed: 24168980
BMJ. 1999 Jan 9;318(7176):86-91
pubmed: 9880280
PLoS One. 2014 Feb 26;9(2):e89186
pubmed: 24586581
J Pediatr. 2009 Feb;154(2):296-8
pubmed: 19150677
Am J Epidemiol. 1991 Jun 1;133(11):1135-51
pubmed: 2035517
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Infect Dis. 2019 Jan 7;219(2):197-205
pubmed: 30189092
Lancet. 2008 Oct 11;372(9646):1328-33
pubmed: 18708248
Ann Trop Paediatr. 2005 Mar;25(1):23-7
pubmed: 15814045
Clin Microbiol Infect. 2007 May;13(5):504-9
pubmed: 17263836
J Infect Dis. 1990 Dec;162(6):1283-90
pubmed: 2230258
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
PLoS One. 2012;7(2):e32056
pubmed: 22384139
Infect Dis Ther. 2018 Mar;7(1):87-120
pubmed: 29470837
Lancet. 2017 Sep 2;390(10098):917-918
pubmed: 28689665
J Pediatr. 1981 May;98(5):708-15
pubmed: 7229749
Am J Epidemiol. 1973 Oct;98(4):289-300
pubmed: 4355170
Pediatr Infect Dis J. 2015 Apr;34(4):361-70
pubmed: 25674708
PLoS One. 2015 Nov 05;10(11):e0142192
pubmed: 26540236
Clin Infect Dis. 2009 Nov 1;49(9):1341-9
pubmed: 19788358